These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28444658)

  • 1. Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study.
    Eyre H; Siddarth P; Cyr N; Yang H; Cole S; Forbes M; Lavretsky H
    Pharmacopsychiatry; 2017 Nov; 50(6):256-263. PubMed ID: 28444658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vilazodone: a review in major depressive disorder in adults.
    McCormack PL
    Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
    Sahli ZT; Banerjee P; Tarazi FI
    Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.
    Oosting RS; Chan JS; Olivier B; Banerjee P; Choi YK; Tarazi F
    Psychopharmacology (Berl); 2016 Mar; 233(6):1025-34. PubMed ID: 26758283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vilazodone: a novel antidepressant.
    Choi E; Zmarlicka M; Ehret MJ
    Am J Health Syst Pharm; 2012 Sep; 69(18):1551-7. PubMed ID: 22935937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vilazodone: in major depressive disorder.
    Frampton JE
    CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
    Khan A; Sambunaris A; Edwards J; Ruth A; Robinson DS
    Int Clin Psychopharmacol; 2014 Mar; 29(2):86-92. PubMed ID: 24247740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vilazodone: a new treatment option for major depressive disorder.
    Owen RT
    Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of vilazodone for the treatment of depressive and anxiety disorders.
    Stuivenga M; Giltay EJ; Cools O; Roosens L; Neels H; Sabbe B
    Expert Opin Pharmacother; 2019 Feb; 20(3):251-260. PubMed ID: 30475091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
    Khan A
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vilazodone for the treatment of major depressive disorder.
    Iranikhah M; Wensel TM; Thomason AR
    Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vilazodone for the treatment of depression.
    Lindsey WT
    Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression.
    Katz MM; Tekell JL; Bowden CL; Brannan S; Houston JP; Berman N; Frazer A
    Neuropsychopharmacology; 2004 Mar; 29(3):566-79. PubMed ID: 14627997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.
    Durgam S; Gommoll C; Forero G; Nunez R; Tang X; Mathews M; Sheehan DV
    J Clin Psychiatry; 2016 Dec; 77(12):1687-1694. PubMed ID: 27232052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Double-Blind, Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder and Comorbid Depression.
    Ramaswamy S; Driscoll D; Reist C; Smith LM; Albers LJ; Rose J; Nguyen L; Monga V; Doria R; Hollifield M
    Prim Care Companion CNS Disord; 2017 Aug; 19(4):. PubMed ID: 28858440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
    Dawson LA
    Expert Opin Drug Discov; 2013 Dec; 8(12):1529-39. PubMed ID: 24195711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
    Guay DR
    Consult Pharm; 2012 Dec; 27(12):857-67. PubMed ID: 23229074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.